Rani Therapeutics Holdings (RANI) Long-Term Debt Repayments (2024 - 2025)
Rani Therapeutics Holdings (RANI) posted Long-Term Debt Repayments of $9.5 million for Q4 2025, up 152.59% on a QoQ basis from $3.8 million in Q3 2025, and up 152.59% year-over-year from $3.8 million in Q4 2024.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Long-Term Debt Repayments (2024 - 2025) Analysis & Trends
Rani Therapeutics Holdings has reported Long-Term Debt Repayments for 2 years, with the latest figure at $9.5 million in Q4 2025.
- On a quarterly basis, Long-Term Debt Repayments rose 152.59% year-over-year to $9.5 million in Q4 2025; TTM through Jun 2026 was $13.2 million, a 5.78% increase from a year earlier, with the FY2025 full-year figure at $20.7 million, up 314.44% from the prior year.
- Long-Term Debt Repayments was $9.5 million for Q4 2025 at Rani Therapeutics Holdings, up from $3.8 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $9.5 million in Q4 2025, with the low at $1.2 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 9.47 Mn |
| Sep 30, 2025 | 3.75 Mn |
| Jun 30, 2025 | 3.75 Mn |
| Mar 31, 2025 | 3.75 Mn |
| Dec 31, 2024 | 3.75 Mn |
| Sep 30, 2024 | 1.25 Mn |